ClinicalTrials.Veeva

Menu
L

Liver Center of Texas | Dallas, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Elafibranor
Resmetirom
MGL-3196
Obeticholic Acid
Lanifibranor
HM15211
Cenicriviroc
CVC

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 16 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling
Primary Biliary Cholangitis (PBC)
Drug: Elafibranor
Other: Matched 80 mg placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 f...

Enrolling
NASH - Nonalcoholic Steatohepatitis
Diagnostic Test: Liver Multi Scan

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting
Primary Biliary Cirrhosis
Drug: Elafibranor 80mg
Drug: Placebo

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: HM15211
Drug: Placebo of HM15211

Trial sponsors

Madrigal Pharmaceuticals logo
H
I
Ipsen logo
A
Genfit logo
Hanmi Pharmaceutical logo
I
P
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems